Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth qu ...

Core Insights - Myriad Genetics reported third-quarter revenue of $205.7 million, slightly above analyst estimates of $204.8 million, but experienced a 3.6% year-on-year decline [6] - Adjusted EPS was $0, beating analyst expectations of -$0.01, while adjusted EBITDA reached $10.3 million, significantly exceeding estimates of $5.57 million [6] - The company reaffirmed its full-year revenue guidance at $823 million and EBITDA guidance at $30 million, above analyst estimates of $27.52 million [6] Revenue and Profitability - The average revenue per test faced ongoing challenges, impacting overall market sentiment negatively despite meeting revenue expectations [1] - Operating margin decreased to -11.3%, down from -9.4% in the same quarter last year, indicating operational headwinds [6] Segment Performance - Strong volume growth was noted in the oncology segment, particularly for the MyRisk hereditary cancer test, which management views as a positive development [1] - The company faced pressures from reduced coverage for the GeneSight mental health test and a divested European business, but core test volumes showed signs of stabilization [1] Analyst Insights - Analysts raised questions regarding the balance between commercial investment and profitability, with management emphasizing an organizational redesign to support growth in cancer care while focusing on profit improvement [6] - Concerns were raised about the prenatal market share and operational improvements, with management addressing customer losses and future growth expectations from FirstGene [6] - Questions regarding hereditary cancer testing volume growth were clarified as stemming from improved customer workflows and EMR integration rather than a temporary rebound [6] Pricing and Market Dynamics - Average selling price declines in hereditary cancer tests were attributed to payer mix, biopharma revenue lumpiness, and changes in UnitedHealthcare's policy [6] - Plans to track an expanded provider base and multi-product adoption were highlighted as future key performance indicators [6] Operational Efficiency - Competitive turnaround times for Prequel and FirstGene tests were confirmed, with expectations for FirstGene to align with Prequel at launch [6]